Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and ...
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the ...
Amid restructuring efforts, Bayer has addressed its need for a capital infusion in pharma under a deal to secure 3 billion ...
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...
The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...
The comment-seeking period and probe tie back to Sanofi’s marketing for its flu shot for adults ages 60 and over, which is ...
After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings ...
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results